Delivery Order SPE2DX22D0010-SPE2D826FBP77
- Not listed
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Nucynta ER (tapentadol extended-release) 100mg tablets, valued at $6,005.43. This firm fixed-price delivery order, which represents a child contract under a larger vehicle, is scheduled for completion by August 5, 2025, and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The award was made through open...
- The Department of Defense's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on November 7, 2025, for the supply of Nucynta ER (extended-release tapentadol) 100mg tablets, with a contract ceiling value of $11,928.39 and a completion date of November 10, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under the company's broader Indefinite Delivery Contract (IDC) vehicle with Defense Logistics Agency Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 2, 2025, for the supply of Nucynta (tapentadol) 50 mg tablets in a quantity of 100 units, with a contract ceiling value of $4,413.94. This delivery order represents a firm fixed price, non-set-aside contract with a completion date of December 3, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award is issued as a child contract under AmerisourceBergen's...
- The Defense Logistics Agency Medical Supply Chain awarded a $2,917.26 firm fixed-price delivery order to AmerisourceBergen Drug Corp on October 6, 2025, for the supply of Nucynta ER (extended-release tapentadol) 50mg tablets. This is a non-set-aside competitive award with an ultimate completion date of October 7, 2025, to be performed at the contractor's Conshohocken, Pennsylvania facility. The delivery order represents a child contract under AmerisourceBergen's larger pharmaceutical prime...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 4, 2025, for the supply of Nucynta (tapentadol) 50 mg tablets in quantities of 100, valued at $2,251.72. This firm fixed-price delivery order is not set-aside and will be completed by November 5, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement supporting federal medical supply needs,...
- The Defense Logistics Agency awarded a Delivery Order (4570020886) to AmerisourceBergen Drug Corp for the supply of Nucynta ER 100 mg tablets (60-count) on November 17, 2025, with an ultimate completion date of November 18, 2025. The contract is valued at $2,850.28 under a firm fixed-price arrangement with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on September 8, 2025, for 60 tablets of Nucynta ER 200 mg. This firm fixed-price, competitively awarded contract carries a ceiling value of $2,411.52 and is scheduled for completion by September 9, 2025. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on December 3, 2025, for the supply of Nucynta ER 150 mg tablets (60-count). The contract is competitively awarded with no set-aside designation and carries a ceiling value of $2,817.62 under a firm fixed-price arrangement. This delivery order is part of AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA...
- AmerisourceBergen Drug Corp was awarded a firm fixed price delivery order valued at $14,565.84 for Nucynta ER (extended-release tapentadol) 100mg tablets by the Defense Logistics Agency's Medical Supply Chain on July 31, 2025, with an ultimate completion date of August 1, 2025. The contract was awarded without set-aside designation through competitive procurement to support federal medical supply requirements. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Nucynta ER 100 mg tablets (60-count units) with a ceiling value of $1,472.04 and a firm fixed price structure. This is a non-set-aside, competitively awarded contract with a completion date of September 29, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical...
- SPE2DX22D0010Indefinite Delivery Contract
- SPE2DX22D0010-SPE2D826FBP77Delivery Order
The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on December 8, 2025, for the supply of Nucynta ER (extended-release tapentadol) 200mg tablets. This is a firm fixed-price contract with a ceiling value of $2,186.26 and an ultimate completion date of December 9, 2025. The award is a non-set-aside competitive procurement, reflecting the contractor's capability to meet federal pharmaceutical supply requirements through open competition. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive $1 billion global pharmaceutical support vehicle running through December 2026. As a major pharmaceutical distributor, AmerisourceBergen serves as a critical vendor for federal military and veteran healthcare systems, supplying an extensive portfolio of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. The company's position as a pharmaceutical prime vendor reflects its established capacity to fulfill diverse federal medical supply needs through flexible contract mechanisms supporting the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.2k | 12/7/25 |